Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMKLMG6)

Drug Name

KN035 Drug Info

Synonyms

Envafolimab

Indication

Disease Entry	ICD 11	Status	REF
Pleomorphic sarcoma	2B54	Phase 2	[1]
Solid tumour/cancer	2A00-2F9Z	Phase 2	[2]
Advanced malignancy	2A00-2F9Z	Phase 1	[3]

Cross-matching ID

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Programmed cell death 1 ligand 1 (PD-L1)	TT8ZLTI	PD1L1_HUMAN	Not Available	[3]

------------------------------------------------------------------------------------

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease

Pleomorphic sarcoma

ICD Disease Classification

2B54

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Programmed cell death 1 ligand 1 (PD-L1)	DTT	CD274	4.38E-07	0.37	2.1

Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1	ClinicalTrials.gov (NCT04480502) ENVASARC: Envafolimab And Envafolimab With Ipilimumab In Patients With Undifferentiated Pleomorphic Sarcoma Or Myxofibrosarcoma (ENVASARC). U.S. National Institutes of Health.
2	ClinicalTrials.gov (NCT04891198) ENVAFOLIMAB Single-agent Treatment in Patients With Advanced Solid Tumors. U.S. National Institutes of Health.
3	Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730.